Full-Time

Financial Analyst

Multiple Teams

Posted on 7/29/2025

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Ann Arbor, MI, USA

In Person

Category
Finance & Banking (1)
Required Skills
Financial analysis
Requirements
  • Bachelor’s degree in accounting, Finance, or a related degree.
  • 5+ years’ experience in an accounting/finance position.
  • Excellent written and verbal communication skills.
  • Proficient with database and spreadsheet programs; experience in using financial/accounting and/or general ledger information systems.
  • Knowledge of generally accepted accounting principles.
Responsibilities
  • Under the local controller's general supervision, performs various functions in the accounting cycle, from general ledger review to financial analysis.
  • Assist with monthly cost center review, adjustments, closing, reporting, and analytics.
  • Participate in annual budget preparation, budget monitoring, and other financial reports required by the group and local controlling.
  • Monthly review of Cost Center expenses focusing on understanding budget deviations.
  • Monthly reconciliation of goods receipts and invoice receipts.
  • Monthly review and adjustments of month-end sales/delivery cutoffs for proper revenue recognition.
  • Monthly review and processing of service order settlements.
  • Monthly/Quarterly adjusting journal entry preparation (inventory devaluation, warranties, and accruals).
  • Ad hoc query reports/requests from Business Managers and/or Group/Local Controlling.
  • Assist with financial reports as required by law (i.e., Government Census re).
  • Other duties / special projects as needed.
  • Ability to travel (1-2 trips/year) with potential for international travel.
Desired Qualifications
  • Experience with SAP.
  • Strong attention to detail.
  • Strong analysis and critical thinking skills.
  • Ability to identify, analyze, and solve problems.
  • Ability to build and maintain effective working relationships with others.
  • Ability to keep commitments and take responsibility for one's actions.
  • Ability to work independently and collaborate as part of a team.
  • Ability to organize, prioritize, and plan work activities and projects to meet deadlines.
  • Ability to adapt quickly to changing demands.
  • Ability to be flexible with time around closing periods.

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Goldman Sachs upgrades Sartorius Stedim Biotech to Buy rating.
  • Sartorius achieves 3.5 billion euros sales revenue in 2025.
  • Management forecasts 5-9% sales growth for 2026 with MATTEK contributions.

What critics are saying

  • Thermo Fisher undercuts Sartorius bioreactors, capturing 15-20% market share.
  • Danaher's Cytiva launches Sartocon competitor with 30% higher throughput.
  • Chinese clones replicate Arium Mini at 40% lower cost, eroding Asia sales.

What makes Sartorius unique

  • Sartorius launches Arium Mini Extend for versatile Type 1 water dispensing.
  • Sartorius opens $100M Bioanalytics CoE in Ann Arbor, Michigan.
  • Sartorius partners with Sanofi on downstream process intensification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

IT Juzi
Aug 12th, 2025
Nanotein secures $3M strategic investment

Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.

INACTIVE